For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Gen9, Inc.

Calculating rank

USPTO Granted Patents = 44

% Expired Patents = 36.4

CIPO Patents = 16

EPO Patents = 22

Trademarks = 1

Forward Citations = 1,103

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Joseph M Jacobson (28 out of 143 patents)

Michael E Hudson (14 out of 15 patents)

Daniel Schindler (13 out of 14 patents)

4. Larry Li-Yang Chu (11 out of 11 patents)

5. Li-yun A Kung (8 out of 9 patents)

6. Senthil Ramu (7 out of 7 patents)

7. Scott S Lawton (6 out of 7 patents)

8. Andrew V Oleinikov (6 out of 10 patents)

9. Martin J Goldberg (5 out of 57 patents)

10. Ishtiaq E Saaem (4 out of 4 patents)

11. George M Church (3 out of 205 patents)

12. Andrew Wilson (3 out of 11 patents)

13. Mark A Fauci (3 out of 5 patents)

14. Giles F Hall (2 out of 2 patents)

15. Li-Yun A Kung (2 out of 2 patents)

Core Competencies:

Nucleic Acids

Polynucleotides

High Throughput Sequencing

Oligonucleotides

Protein Arrays

Microarrays

Gene Synthesis

Microfluidic Devices

DNA Error Reduction

Droplet Manipulation

Enzyme Catalysis

44 patents: Sort by Forward Citations

1. 12668791 - COMPOSITIONS AND METHODS FOR MULTIPLEX NUCLEIC ACIDS SYNTHESIS (2026-06-30),

2. 12241057 - Methods for nucleic acid assembly and high throughput sequencing (2025-03-04),

3. 11845054 - Methods and devices for nucleic acids synthesis (2023-12-19),

4. 11702662 - Compositions and methods for high fidelity assembly of nucleic acids (2023-07-18),

5. 11242523 - Compositions, methods and apparatus for oligonucleotides synthesis (2022-02-08),

6. 11130948 - Compositions and methods for multiplex nucleic acids synthesis (2021-09-28),

7. 11084014 - Methods and devices for nucleic acids synthesis (2021-08-10),

8. 11072789 - Methods for nucleic acid assembly and high throughput sequencing (2021-07-27),

9. 11071963 - Assembly of high fidelity polynucleotides (2021-07-27),

10. 11015191 - Methods and devices for high fidelity polynucleotide synthesis (2021-05-25),

11. 10982208 - Protein arrays and methods of using and making the same (2021-04-20),

12. 10927369 - Methods for sorting nucleic acids and multiplexed preparative in vitro cloning (2021-02-23),

13. 10829759 - Methods and apparatuses for chip-based DNA error reduction (2020-11-10),

14. 10774325 - Microarray synthesis and assembly of gene-length polynucleotides (2020-09-15),

15. 10640764 - Microarray synthesis and assembly of gene-length polynucleotides (2020-05-05),

Company Overview

Gen9, Inc., based in Boston, MA, specializes in advanced nucleic acid technologies, focusing on the synthesis and assembly of nucleic acids. The company is recognized for its expertise in high throughput sequencing and the production of oligonucleotides, which are essential for various applications in genomics and synthetic biology. Gen9's innovative approaches to multiplex nucleic acids synthesis and polynucleotide synthesis position it as a key player in the biotechnology sector, contributing to advancements in research and development across multiple scientific fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

44 Patents

#55 in Boston, MA

#456 in Massachusetts

#7,960 in US

#15,768 in the World

Boston, MA, United States of America

Gen9, Inc.

Forward Citations = 1,103

27 inventors:

Joseph M Jacobson (28 out of 143 patents)

Michael E Hudson (14 out of 15 patents)

Daniel Schindler (13 out of 14 patents)

4. Larry Li-Yang Chu (11 out of 11 patents)

5. Li-yun A Kung (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gen9, Inc.. Retrieved from https://idiyas.com/company/gen9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…